Zobrazeno 1 - 10
of 507
pro vyhledávání: '"I Mincu"'
Autor:
Julia Pohl, Matthias Totzeck, Raluca‐I. Mincu, Simone M. Margraf, Lena Scheipers, Lars Michel, Amir A. Mahabadi, Lisa Zimmer, Tienush Rassaf, Ulrike B. Hendgen‐Cotta
Publikováno v:
ESC Heart Failure, Vol 9, Iss 5, Pp 3533-3542 (2022)
Abstract Aims While immune checkpoint inhibitor (ICI) therapy significantly improves survival rates in advanced melanoma, ICI can evoke severe immune‐related cardiovascular adverse events. Right ventricular (RV) dysfunction negatively impacts the o
Externí odkaz:
https://doaj.org/article/aae44109e7774531bdcef5596b923f82
Autor:
Lars Michel, Raluca I. Mincu, Simone M. Mrotzek, Sebastian Korste, Ulrich Neudorf, Tienush Rassaf, Matthias Totzeck
Publikováno v:
ESC Heart Failure, Vol 7, Iss 2, Pp 423-433 (2020)
Abstract Aims Childhood cancer therapy is associated with a significant risk of therapy‐related cardiotoxicity. This meta‐analysis aims to evaluate cardiac biomarkers for the detection of cancer therapy‐related left ventricular (LV) dysfunction
Externí odkaz:
https://doaj.org/article/9c7ced8031624bcca594b90c48bfc901
Publikováno v:
ESC Heart Failure, Vol 6, Iss 4, Pp 856-862 (2019)
Abstract Aims Conventional cytotoxic chemotherapy is still among the most effective treatment options for many types of cancer. However, cardiotoxicity, notably the decrease in left ventricular function under these regimens, can impair prognosis. Thu
Externí odkaz:
https://doaj.org/article/cfcd496d5d4848bfa3f2706f8075639f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Raluca I. Mincu, Simone M. Mrotzek, Mohamed El Gabry, Rolf Alexander Jánosi, Merve Akdeniz, Arjang Ruhparwar, Matthias Totzeck, Alexander Lind, Lena Hinrichs, Amir A. Mahabadi, Tienush Rassaf
Publikováno v:
JACC: CardioOncology. 2:735-743
Background The use of transcatheter aortic valve replacement (TAVR) in cancer survivors and patients with active cancer (AC) in cancer survivors and patients with active cancer (AC) is expanding, suggesting a need to adjust the indications and risk a
Autor:
Stephan Settelmeier, Amir A. Mahabadi, Fadi Al-Rashid, Tienush Rassaf, Lars Michel, Matthias Totzeck, Raluca I. Mincu
Publikováno v:
European Journal of Heart Failure. 22:350-361
Aims Cardiac biomarkers are a mainstay in diagnosis of cardiovascular disease but their role in cardio-oncology has not yet been systematically evaluated. This meta-analysis aims to determine whether cardiac troponins and (N-terminal pro) brain natri
Autor:
Amir A. Mahabadi, Lena F Lampe, Matthias Totzeck, Tienush Rassaf, Rainer Kimmig, Raluca I. Mincu
Publikováno v:
Journal of Clinical Medicine
Volume 10
Issue 17
Journal of Clinical Medicine, Vol 10, Iss 3890, p 3890 (2021)
Volume 10
Issue 17
Journal of Clinical Medicine, Vol 10, Iss 3890, p 3890 (2021)
Background: Anthracycline-based chemotherapy (ANT) remains among the most effective therapies for breast cancer. Cardiotoxicity from ANT represents a severe adverse event and may predominantly manifest as heart failure. While it is well-recognised th
Autor:
S Hendricks, Tienush Rassaf, Matthias Totzeck, Iryna Dykun, Raluca I. Mincu, Amir A. Mahabadi, Bastian Balcer
Publikováno v:
European Journal of Preventive Cardiology. 27:1675-1678
Autor:
Amir A. Mahabadi, Ulf Landmesser, Markus S. Anker, Ulrich Keller, Martin Schuler, Ria Ludwig, Sara Hadzibegovic, Fadi Al-Rashid, Stefan D. Anker, Alessia Lena, Tienush Rassaf, Raluca I. Mincu, Lena Hinrichs, Simone M. Mrotzek, Laura Johannsen, Lars Michel, Matthias Totzeck
Publikováno v:
Clinical Research in Cardiology
Background With improvement of cancer-specific survival, comorbidities and treatment-related side effects, particularly cardiovascular toxicities, need close attention. The aim of the present study was to evaluate clinical characteristics and outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5403523b9d58d9a46b26467cf14e8f6a
https://www.ncbi.nlm.nih.gov/pubmed/32743679
https://www.ncbi.nlm.nih.gov/pubmed/32743679
Autor:
Alexander, Lind, Matthias, Totzeck, Amir A, Mahabadi, Rolf A, Jánosi, Mohamed, El Gabry, Arjang, Ruhparwar, Simone M, Mrotzek, Lena, Hinrichs, Merve, Akdeniz, Tienush, Rassaf, Raluca I, Mincu
Publikováno v:
JACC: CardioOncology
Background The use of transcatheter aortic valve replacement (TAVR) in cancer survivors and patients with active cancer (AC) in cancer survivors and patients with active cancer (AC) is expanding, suggesting a need to adjust the indications and risk a